Ikarian Capital, LLC Mirati Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $2.74 Million - $4.07 Million	-75,000 Reduced 69.38%	33,100 $1.23 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $4.46 Million - $10.7 Million	108,100 New	108,100 $4.9 Million
Q4 2020 Feb 12, 2021	SELL	$162.05 - $240.27 $5.67 Million - $8.41 Million	-35,000 Reduced 90.77%	3,557 $781,000
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $4.37 Million - $6.45 Million	38,557 New	38,557 $6.4 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.